高风险患者在减重手术前使用GLP-1激动剂:一项队列研究
该单中心回顾性研究纳入31例BMI>50 kg/m2的减重手术患者,比较术前使用与未使用GLP-1激动剂的结局。使用GLP-1激动剂与BMI降低5.5±3.2点相关,对照组降低2.9±2.4点(p=0.026);两组手术等待时间无差异(p=0.332),围术期并发症无差异(p=0.245),未报告GLP-1相关并发症。
要点
- BMI>50 kg/m2患者术前使用GLP-1激动剂与更大幅度的BMI下降相关。
- GLP-1激动剂使用未增加手术等待时间或围术期并发症发生率。
- 术前GLP-1激动剂对围术期及长期结局的影响需进一步研究。
核心结论
- 在BMI>50 kg/m2患者中,术前使用GLP-1激动剂与减重手术前更显著的体重下降相关,且未增加手术等待时间或并发症发生率。
- 术前使用GLP-1激动剂的长期影响需进一步研究,该治疗可能改善极高BMI人群的围术期和长期结局。
研究设计与样本
- 单中心回顾性队列研究,纳入BMI>50 kg/m2的减重手术患者31例,按术前是否使用GLP-1激动剂分组比较。
- 所有患者均接受内科、外科、精神科和营养评估与咨询。
主要发现
- 18例(58%)患者术前接受GLP-1激动剂治疗。
- GLP-1激动剂组BMI降低5.5±3.2点,对照组降低2.9±2.4点(p=0.026)。
- 两组手术前在减重项目中平均等待时间无差异(p=0.332)。
- 术前未报告与GLP-1使用相关的并发症,两组围术期并发症无差异(p=0.245)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Body mass index (BMI) > 50 kg/m2 is associated with relatively increased morbidity and mortality with bariatric surgery (BS). There is reluctance to consider these patients operative candidates without preoperative weight loss. Glucagon-like peptide-1 (GLP-1) agonists have demonstrated effective weight loss in the post-BS setting. This study aims to determine the safety and efficacy of GLP-1 agonists in the pre-habilitation of patients with BMI > 50 kg/m2. METHODS: This is a retrospective review of bariatric surgery patients with BMI > 50 kg/m2 from a single bariatric center. Patients were compared by preoperative GLP-1 therapy status. All patients received medical, surgical, psychiatric, and nutritional evaluation and counseling. Preoperative BMI, change in weight from program intake until surgery, time to surgery, and perioperative complications were evaluated. RESULTS: 31 patients were included in the analysis. 18 (58%) received a GLP-1 agonist preoperatively. GLP-1 agonist use was associated with a 5.5 ± 3.2-point reduction in BMI compared to 2.9 ± 2.4 amongst controls (p = 0.026). There was no difference in the mean length of time in the bariatric program prior to surgery between groups (p = 0.332). There were no reported complications related to GLP-1 use in the preoperative setting and no difference in perioperative complications between groups (p = 0.245). DISCUSSION: GLP-1 agonist use in patients with a BMI > 50 kg/m2 results in significantly more weight loss prior to bariatric surgery, without increased time to surgery or complication rate. Further study is required to evaluate the long-term impact of preoperative GLP-1 agonist use prior to bariatric surgery. This therapy may improve perioperative and long-term outcomes in the very high-risk BMI population.
引用
- Ilanga M, Heard JC, McClintic J, et al. Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study. Surg Endosc. 2023. PMID: 37700013. doi:10.1007/s00464-023-10387-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。